Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.
about
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseasePhosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseaseCyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoterThe MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579.Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoformCrystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine bindingPDE4 inhibitors: current statusBronchodilator and anti-inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytesPhosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment responseDelineation of RAID1, the RACK1 interaction domain located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5.The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthmaLung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors.Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory DiseasesCrystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivityStereoselective synthesis of novel pyrazole derivatives using tert-butansulfonamide as a chiral auxiliaryCan roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysisSelective Phosphodiesterase 4B Inhibitors: A ReviewThe unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domainsERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regionsRolipram, a specific type IV phosphodiesterase inhibitor, ameliorates aspirin-induced gastric mucosal injury in ratsIn vitro PKA phosphorylation-mediated human PDE4A4 activationTAPAS-1, a novel microdomain within the unique N-terminal region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acidIloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungsAccelerated calcium influx and hyperactivation of neutrophils in chronic granulomatous diseaseEffects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injuryPhosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected miceThe selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in micebeta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to GiImpaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient miceThe CSC proteins FAP61 and FAP251 build the basal substructures of radial spoke 3 in ciliaInduction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responsesIdentification, characterization and subcellular localization of TcPDE1, a novel cAMP-specific phosphodiesterase from Trypanosoma cruzi.Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn ratsCompartmentalized cyclic adenosine 3',5'-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains.The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma.Immunomodulation by thalidomide and thalidomide analoguesTherapeutic strategies for allergic diseases.In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptida
P2860
Q24202545-A8DAB3CF-14EE-431F-AB2A-921E116C6276Q24234493-8030E75F-0D98-47C5-A70A-A95E4D92EC21Q24301633-E64E9C25-0C75-4341-B307-F4E538A7390BQ24533566-ADE80F0E-D995-4ADD-8115-00664FB2CFB4Q24535564-6578E3D7-E1AA-4EE3-9228-A83E1B228A50Q24562006-841262BC-AA71-4167-B579-52EEB6D9A5F1Q24651926-6EE0968E-D487-4110-BCC1-D5C2132D79EEQ24672043-78E75BF0-C64F-4BCB-8B82-0DE7FE647D62Q24674385-2BDBB676-6355-42AF-AA3B-A7845008BA39Q24801846-9506CA26-DCE2-4D2F-88DA-C7CC365777FBQ24804029-FC28C3A3-C191-4749-BFE8-32319D8A3BE1Q24815216-9CFCE28F-C469-43D9-ABFB-B3729DF8F023Q25255769-DF42C39D-B429-4FCD-BBF7-EDBE3C98DDFCQ26750377-FC522394-ED80-4FF6-91C6-C0FF15FD4238Q27642760-3AE780F2-AACF-4130-A7FB-B803A60D5518Q27677514-E8CE710C-C2B5-4E89-A92C-C8BED28490EBQ28070108-7B81D1E3-6B9E-4442-9C4B-9ECECFC89762Q28081071-DA32BCE1-1530-4A88-A0B2-EE2BA5F8ACEAQ28138448-C3ECC5D3-0B7F-4277-9FD2-AEBF8F96023FQ28145238-82D99072-8EAE-482B-932C-1ACB9E7F8CCBQ28182109-84D19D19-B798-486B-B8BF-B1452317AAACQ28202278-CAE8A9BC-3723-42A6-8F1D-42325E123B72Q28216705-C933160D-321E-4FE5-9BA6-E8855C967E3CQ28218337-3D936E18-F24F-4E6D-8CF2-9C07FE22D5B2Q28350996-A8AC1134-165F-4F6E-8AAD-5AEE0C609BA3Q28362714-98962711-E46F-47A3-BE14-806C26D19267Q28477281-A8E86D2B-9FE9-4323-948F-E250E41D0A09Q28487329-9796DB19-306D-4677-9B73-7E6BA33D4F2CQ28576849-1EE847B6-3B37-4A3E-B73C-301D6702AAA6Q28594618-FEEB211E-52D9-4AA7-BF0F-E6454C69B84AQ30638674-95F016A8-0726-4E36-9B98-17B0417A8E96Q30732295-941BA9EC-A4DD-412C-AA1C-B6F8CCE30AD7Q31011288-EEDF9E6A-DC55-4701-8FD7-3A6A9482D2A8Q33341310-F3DE3AD6-400D-4682-B2C5-51D00DC4027CQ33378441-7A226ACA-A4EC-428E-A5D2-E70D39F1AFC6Q33721181-AF1441EA-D5E7-4FF6-95F5-F53E9D95ACFCQ33737175-DE7C4663-5480-4EF9-A9C3-2DE975B4E430Q33782386-DAEBD08E-DF39-4B14-AE50-16BB42F21356Q33787614-4A68671E-0736-4D4D-88A9-289D7DC90A32Q33804636-D6A3DED8-5E72-43EB-9CC5-A314E494F88B
P2860
Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.
@en
type
label
Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.
@en
prefLabel
Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.
@en
P2860
P1476
Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.
@en
P2093
P2860
P304
P356
10.1164/AJRCCM.157.2.9708012
P407
P577
1998-02-01T00:00:00Z